AbbVie Inc. Long-term assets (Other)

Long-term assets (Other) of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long-term assets (Other) growth rates and interactive chart. All other non-current assets that do not fit the categories above.

Highlights and Quick Summary

  • Long-term assets (Other) for the quarter ending June 29, 2021 was $4.74 Billion (a 0.38% increase compared to previous quarter)
  • Year-over-year quarterly Long-term assets (Other) increased by 25.32%
  • Annual Long-term assets (Other) for 2020 was $3.83 Billion (a 99.95% increase from previous year)
  • Annual Long-term assets (Other) for 2019 was $1.91 Billion (a 58.36% increase from previous year)
  • Annual Long-term assets (Other) for 2018 was $1.21 Billion (a -8.9% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long-term assets (Other) of AbbVie Inc.

Most recent Long-term assets (Other)of ABBV including historical data for past 10 years.

Interactive Chart of Long-term assets (Other) of AbbVie Inc.

AbbVie Inc. Long-term assets (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $4,736.0 $4,718.0
2020 $3,825.0 $3,779.0 $3,851.0 $2,638.0 $3,825.0
2019 $2,288.0 $1,677.0 $1,589.0 $1,567.0 $1,913.0
2018 $1,208.0 $943.0 $909.0 $903.0 $1,208.0
2017 $1,326.0 $1,327.0 $1,305.0 $1,263.0 $1,326.0
2016 $1,212.0 $1,550.0 $1,445.0 $1,328.0 $1,212.0
2015 $1,149.0 $1,235.0 $1,181.0 $1,755.0 $1,149.0
2014 $1,480.0 $801.0 $795.0 $803.0 $1,480.0
2013 $767.0 $1,150.0 $1,693.0 $1,715.0 $767.0
2012 $835.0 $835.0
2011 $784.0 $784.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.